J&J Expects Persistent Pricing Pressure Into 2019

 
• By Jessica Merrill

CEO Alex Gorsky highlighted growing public concern over US drug costs during J&J's Q4 earnings call, pressing for more transparency and value-based health care. The company's net drug prices declined more than 6% in 2018, he added.

Hand drawing of green and red chalk in up and down arrow shape on black board background - Image

More from Earnings

More from Business